Drugs / FS VH S/D 4 s-apr
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01112735 | May → Dec 2010 | — | Baxter Healthcare Corporation | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FS VH S/D 4 s-apr | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01112735 ↗ |
| Modality | Protein / enzyme biologic | “Biological: FS VH S/D 4 s-apr (= two-component fibrin sealant, double virus inactivated, made from pooled human plasma)” NCT01112735 ↗ |
| Route | Other | “Dosage form: spray (aerosolized sealant), Dosage frequency: once (1 layer). ARTISS will be applied onto the fascia or the wound bed.” NCT01112735 ↗ |